ABBOTT LABORATORIES vs NOVO NORDISK A/S, two Drug Manufacturers stocks. A side-by-side on valuation, growth, margins, returns, and what each price is betting.
Where ABT and NVO diverge most: on debt / equity, ABT reads 0.65 and NVO reads 0.00; on return on invested capital, ABT reads 6.6% and NVO reads 51.6%. The rest of the comparable metrics sit closer together. What ABT's price implies is a bet that sits within the historical range (whole-company basis). The bull and bear cases for each are in their full reports below.
| Metric | ABT | NVO |
|---|---|---|
| Price | $105.72 | $47.08 |
| Market cap | $184.7B | $209.2B |
| Sector | Drug Manufacturers | Drug Manufacturers |
| Stage | Mature | Growth |
| Implied growth (priced in) | +13.7% | — |
| P/E | 29.6 | 13.9 |
| P/B | 3.50 | 7.33 |
| P/S | 4.09 | 4.60 |
| EV/EBITDA | 23.1 | 9.8 |
| Revenue growth | +6.6% | +22.1% |
| Gross margin | — | 81.0% |
| Operating margin | 12.1% | 41.3% |
| Net margin | 13.9% | 33.1% |
| Return on equity | 11.9% | 52.8% |
| Return on assets | 5.7% | 18.9% |
| Return on invested capital | 6.6% | 51.6% |
| FCF yield | 4.0% | 4.2% |
| Dividend yield | 2.3% | — |
| Debt / equity | 0.65 | 0.00 |
| Current ratio | 1.39 | 0.80 |
| Altman Z (solvency) | 7.16 | 4.20 |
| Piotroski F (quality) | 6 / 9 | 4 / 9 |
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
The stronger value is highlighted per metric where one is strictly better on that single number; it is not an overall verdict on either company. For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.